Last reviewed · How we verify
Sodium-Glucose Co-Transporter-2 Inhibitors in Lupus Nephritis (Dapa-Active LN)
Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure. Sodium-glucose co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for people with other causes of chronic kidney disease. This pilot and feasibility randomized clinical trial will test the use of dapagliflozin versus placebo in addition to standard of care treatment for patients with early and active lupus nephritis, a group who has not been included in past trials.
Details
| Lead sponsor | Brigham and Women's Hospital |
|---|---|
| Phase | Phase 4 |
| Status | NOT_YET_RECRUITING |
| Enrolment | 33 |
| Start date | 2026-06-01 |
| Completion | 2030-01 |
Conditions
- Lupus Nephritis (LN)
Interventions
- Dapagliflozin (10Mg Tab) along with standard medical therapy
- Placebo
Primary outcomes
- Proportion of eligible enrolled — 3 years
The overall proportion of identified as potentially eligible/pre-screened patients who enroll in the trial
Countries
United States